Kaken Pharmaceutical Co., Ltd. (TYO:4521)
Japan
· Delayed Price · Currency is JPY 4,278.00
+73.00 (1.74%)
Feb 5, 2025, 3:30 PM JST
Kaken Pharmaceutical Cash Flow Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Net Income | 23,373 | 9,796 | 6,817 | 13,885 | 18,657 | 26,592 | Upgrade
|
| Depreciation & Amortization | 2,649 | 2,753 | 2,568 | 2,486 | 2,318 | 2,761 | Upgrade
|
| Loss (Gain) From Sale of Assets | 139 | 167 | 1,911 | 2,896 | -333 | 348 | Upgrade
|
| Loss (Gain) From Sale of Investments | 537 | -13 | -1 | -1 | -115 | - | Upgrade
|
| Other Operating Activities | -1,973 | -3,788 | -4,407 | -4,431 | -5,517 | -7,807 | Upgrade
|
| Change in Accounts Receivable | 3,003 | -4,559 | 972 | 392 | 1,251 | 8,539 | Upgrade
|
| Change in Inventory | 994 | -1,603 | -583 | 241 | -2,923 | 1,446 | Upgrade
|
| Change in Accounts Payable | -2,236 | 880 | 280 | -2,630 | -112 | -3,576 | Upgrade
|
| Change in Other Net Operating Assets | 268 | -1,056 | 1,696 | 498 | 1,154 | -835 | Upgrade
|
| Operating Cash Flow | 26,754 | 2,577 | 9,253 | 13,336 | 14,380 | 27,468 | Upgrade
|
| Operating Cash Flow Growth | 936.57% | -72.15% | -30.62% | -7.26% | -47.65% | 30.00% | Upgrade
|
| Capital Expenditures | -3,088 | -1,861 | -1,987 | -2,986 | -1,973 | -2,159 | Upgrade
|
| Sale of Property, Plant & Equipment | 1 | 1 | 12 | 704 | 874 | - | Upgrade
|
| Cash Acquisitions | - | - | - | -4,975 | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -181 | -306 | -219 | -271 | -313 | -43 | Upgrade
|
| Investment in Securities | 308 | 516 | -195 | 5 | 124 | - | Upgrade
|
| Other Investing Activities | -4,185 | -4,204 | -238 | -365 | -356 | -326 | Upgrade
|
| Investing Cash Flow | -7,145 | -5,854 | -2,627 | -7,888 | -1,644 | -2,528 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | - | -25 | Upgrade
|
| Total Debt Repaid | - | - | - | - | - | -25 | Upgrade
|
| Net Debt Issued (Repaid) | - | - | - | - | - | -25 | Upgrade
|
| Repurchase of Common Stock | - | - | -1,340 | -2,414 | -2,940 | -4,252 | Upgrade
|
| Dividends Paid | -5,684 | -5,657 | -5,649 | -5,714 | -5,811 | -5,896 | Upgrade
|
| Other Financing Activities | -1 | -1 | -1 | -1 | -1 | - | Upgrade
|
| Financing Cash Flow | -5,684 | -5,658 | -6,990 | -8,129 | -8,752 | -10,173 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | - | - | - | 1 | -1 | -1 | Upgrade
|
| Net Cash Flow | 13,925 | -8,935 | -364 | -2,680 | 3,983 | 14,766 | Upgrade
|
| Free Cash Flow | 23,666 | 716 | 7,266 | 10,350 | 12,407 | 25,309 | Upgrade
|
| Free Cash Flow Growth | 2329.77% | -90.15% | -29.80% | -16.58% | -50.98% | 31.67% | Upgrade
|
| Free Cash Flow Margin | 27.13% | 0.99% | 9.96% | 13.61% | 16.55% | 28.36% | Upgrade
|
| Free Cash Flow Per Share | 624.93 | 18.97 | 193.39 | 272.53 | 321.51 | 646.63 | Upgrade
|
| Cash Interest Paid | 21 | 17 | 17 | 17 | 17 | 17 | Upgrade
|
| Cash Income Tax Paid | 1,976 | 3,788 | 4,409 | 4,431 | 5,516 | 7,807 | Upgrade
|
| Levered Free Cash Flow | 19,617 | -1,299 | 7,486 | 8,025 | 9,418 | 21,379 | Upgrade
|
| Unlevered Free Cash Flow | 19,631 | -1,289 | 7,497 | 8,036 | 9,429 | 21,390 | Upgrade
|
| Change in Net Working Capital | -5,513 | 7,821 | -2,135 | 1,859 | 1,721 | -4,261 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.